Revenio Group Oyj - Company Announcement

Revenio Group Corporation: Icare and Iridex Corporation enter into distribution cooperation

Revenio Group Corporation, Stock Exchange Release, May 18, 2015 at 9:00

ICARE AND IRIDEX CORPORATION ENTER INTO DISTRIBUTION COOPERATION

Revenio Group Corporation's subsidiary Icare Finland Plc has signed a
distribution agreement with US-based Iridex Corporation related to Icare's TA01i
instrument. Iridex plans to package the Icare TA01i with the Iridex Total
Glaucoma Solution which includes the newly launched Cyclo G6 laser and the
proprietary MicroPulse® P3 device dedicated specifically to treat patients
diagnosed with a range of glaucoma disease states. The Icare TA01i aids the
physician in the diagnosis of glaucoma as well as post-operative assessment and
monitoring of the patient's intra-ocular pressure.

Iridex sold its first new Cyclo G6 glaucoma laser along with MicroPulse® P3
disposable devices during the first quarter of 2015. The MicroPulse® P3 device
offers a repeatable, minimally invasive approach to slowing the progress of the
disease and pushing off the need for more invasive surgical intervention. The
Icare TA01i tonometer revolutionizes effective, early glaucoma detection by
making the intra-ocular pressure measuring routine quick and easy for the
patient as well as the physician."Cooperation with Iridex broadens the market reach of both organizations where
the Icare and Iridex equipment and disposables may be offered to glaucoma
physicians as part of a complete system. Iridex, as well as Icare are well-known
brands within the ophthalmic community and we expect positive cooperation during
the years to come," states Revenio's CEO Olli-Pekka Salovaara.

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

Iridex Corporation in brief

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing,
manufacturing, and marketing innovative and versatile laser-based medical
systems, delivery devices and consumable instrumentation for the ophthalmology
market. In addition to the US, Iridex markets its products through distributors
to over 100 countries. The Iridex's revenues totaled to USD 42.8 million in
2014 and the shares of the Corporation are listed on NASDAQ Global Market.
www.iridex.com


The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers. The
Revenio Health Tech segment comprises the business operations of Icare Finland
Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis
screening and monitoring. The common denominators of Revenio's business
operations include screening, follow-up and the global need to make cost savings
in health care via preventive measures. Revenio seeks vigorous growth in health
technology, both organically and through acquisitions and mergers. Revenio aims
at developing even more efficient and easily adopted methods for the early-stage
detection of diseases with significance for public health. The focus of
Revenio's screening technology lies on the early detection of glaucoma,
osteoporosis, skin cancer and asthma, and the monitoring of these during the
treatment process.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating
profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group
Corporation is listed on NASDAQ OMX Helsinki. www.revenio.fi




[HUG#1921990]